clinical b here, Thank to getting who clinical importantly, to before moment who take most And KSI-XXX. I everybody the are for our Kodiak It's investigators, data, Kodiak everyone. clinical studies just updated into and afternoon, has whole been the wanted in the quarter exciting you, contributed and Victor, X our team. good participating our team Phase partners a thank of the patients an
clinical So require intravitreal mentioned, to as injections eye medicines current achieve frequent results. Victor best anti-VEGF the in order
this the really data meaningfully an challenge. the of We clinical the of profiles therapies. differentiated platform of support as anti-VEGF treated emerging excited of believe existing potential KSI-XXX of the to developer, our Xb retinal to each Phase the I'm ophthalmologist address standard KSI-XXX and clinical today and KSI-XXX personally major diseases relative So with drug care about ABC in
phase as described KSI-XXX on we're recent on basis program meeting we the the for very net of at Slide and Victor deepening plan of accelerating a basis approval XX This then the was really that indications of discussion a and collaborative and the the the result said, the of data meeting FDA. for So can that anti-VEGF on was achieve key KSI-XXX slide potential in the our the development with end looking here.
So BLA. forma then third wet each And additional be without one supplement. then supplement. that DME two supplement AMD DME for And of study for study one second RVO pivotal pivotal DR an or for a would initial pro in basis and and pivotal a BLA
shown to as The size XX on the information Slide our duration of these the thinking and reflects current studies.
studies big in lift far and pleased making the Now operational going really place we've of infrastructure there. getting so course, put for DAZZLE these with progress a study the and we're a is, that we're
efficiently plan leverage parallel. run And to to so these in additional expand we studies and that
concept provide let's with the the patients proposed the of Slide the scientific A anti-VEGF, common of So in DME studying pivotal patients population KSI-XXX, data changing objectives the we the gears the words and diseases study. are efficacy, in designed most of durability clinical treated is the the Phase Xb to the Phase to will and and that design move believe most current to and update, of Phase with for confidence proof Xb our retinal and in studies. treatment-naive then because data about occlusion. our representative AMD, we first this wet platform and safety, ABC provide vein and us retinal XX. few so most And DR, It's Xb
next design, a I'll criteria the review the as So few just the in the characteristics baseline slides, and retreatment reminder. study briefly
followed Xb RVO then XX, and three treatment-naive criteria. with at disease-specific and in monthly The So doses Phase study, retreatment occurred at received the are to three open-label, dose is the randomized specified patients two retreatments and a or ratio. levels After followed loading next either on study additional monthly are milligram dose thereafter. X.X patients slide, the KSI-XXX milligram the DME to the levels these X AMD, of so the Slide the doses, X:X initial different protocol according they're patients
follow-up was originally and actually, the that extending now and durability, study Now to weeks and we've XX months. period safety, we're duration overall promising seen XX XX treatment weeks, efficacy, or that
Outcomes of protocol change in or ETDRS the or using as anatomy optical vision, which study thickness as is visual subfield retinal measured include best-corrected retinal standard in or acuity and BCVA is testing OCT. change coherence which CST the using central imaging measured tomography
and as geography. color [indiscernible] other fundus in the seen images study also We such and geography, photos OCT
which course, we trials these the investigators designed XX, Slide to Turning criteria evolving knowledge in conjunction understand to of criteria are patient criteria well to chronic patient specific which based activity, each want vision, the in are with retinal populations. individualize and clinical previous disease the Phase state to these and retreatment as our to are KSI-XXX the was Xb The these objective as regimen the disease the and their to on and from based different anatomy, clinical we durability dosing of also meant safety. on understand
the disease most AMD, the retreatment interval the chronic every of maximum case is six the we also which cap wet months. under in is of So study,
the criteria an significant at phase because to there is objective, activity early but meet protocol meets opinion that present other is retreat also specified option investigator their study, have addition in to disease the treatment discretion their this doesn't In the criteria. if
are characteristics On the are Again slide, next the population. the patients three study expect for treatment-naive and baseline characteristics treatment-naive would these what baseline XX, see groups. U.S.-based the all a we different of Slide you
so to or you it's ceiling have diseases your allow possible groups recent how improve the enroll are with even with and does it particular, called patients very and Now so Phase study. the these due retina the some of is, be is as since better studies. good, retinopathy. But underlying improvement vision, X provision specialists Patients the AMD baseline vision in XX, good AMD especially if important better better we vision effect, the sooner XX much, than affect can can wet allow in only presenting vision like the to much so vision baseline in good, in so patients diabetic [indiscernible] as in so study, to DME to
in time characteristics baseline over baseline ago were have might vision are particularly important to done within trials the that back trials, worse. when these been when evaluating looking long and across data So keep mind a
pan-retinal just would wet durability the turning to observed XX, Retina next-generation get say in longer showed extended really data of treated or eyes dosing ago patients to loading we we study. eyes retreatment. treatment encouraging as data data, DME AAO couple XX% Phase that then have latest XB words a a benefit And is maybe a nearly We AMD promising we initial of Slide treated And a about longer in and safety observe interval. presented I three-month in and high AMD typically four initial before or months biologic following has durability wet doses. intravitreal all to XX% to this AAO bring what know, without you So efficacy receiving at DME, And of a very that month and been the three only to disease the burden just Subspecialty Day. was at that
was And with intraocular And for the finally, three appropriate after XXX receiving anti-VEGF also diabetic beyond which vein severity and therapy the signs of over observed to a over diseases. three of through cases saw half in that was patients. all promising the then and typically over no safety XX and We best the retinal quite months treatment achieve across improvement requires weeks patients a encouraging results. doses disease, XXX We only monthly efficacy without were extended after loading occlusion, early strong of retinopathy the doses. inflammation
these to data walk since all retinal just this. time longer high up stability at month follow a vision level in with study, in follow say and over start It's about month three AAO, X, the one to the and weeks XX look patient each of a anatomy I'll diseases were under in have up, and you across follow latest through intervals. through and then about November vision through been patients let's observed and So at now improvements OCT monthly
the First durability AMD turn next to wet data latest patients. in slide of KSI-XXX on XX,
current that data of wet the XX-week approximately period. dosing best as be AMD, two-year the brolucizumab can Victor maintained every HARRIER HAWK on a patients remember agents or studies. three-month over the again with XX% only interval from mentioned, Now, That's in and
XX% even on therapy, other weeks. the as treatment two patients or occasion, month as monthly So of require therapy every remaining often every
So with than our patients better AMD a maintained on or XX-week of therapy in regimen. at wet dosing dosing KSI-XXX to XX% a that, lot four the objective who every are develop is vast majority with do another or better where on five-month patients least of
Since So they can the data. time to up follow see a study and ongoing patient and the were understand they useful swimmer is data we followed so plots, presented you how each review on durability variable is based this transparent were think the have we patients retreated. recruited, and long as for way individual and was when when
Xb many we've their six retreatment until months observed loading after have last five in until the have far the study, not or even patients thus months patients So actually Phase wet longer or of and four that retreatment AMD dose. reached the received first XX% the first
them the after far b or a will patients, loading are about Phase reach without that's of proportion initial retreatment we're of half reaching doses. So cap to so X intriguing high six-month that observing
administered So data an the truly intravitreally interval and achieve with dosing the to ABC underscore emerging of long potential platform therapy. these KSI-XXX
vision best-corrected OCT. at So now in look let's and changes
Let's next XX. slide, turn Slide to the
improvements between visit the data In reached AAO be central to of and change was maintained, dose it's and at XX week and XX. the the date an retinal treatment change between shorter XXXX. with XX who week fluctuations data data we only and week prior to follow-up this X.X that AMD dosing patients, are intervals. the the and These presented after patients, milligram November a consistent thickness levels microns. cut-off continue and between from through through on observed as XX one the on XX.X-micron XX, X.X are So with the X, these the week that the Remember and well. phase, to period subfield three weeks pool XX X effect given favorably wet visual agents with XX, of to acuity anatomy and data durable months This OCT KSI-XXX durability existing OCT, week on only is XX is loading anti-VEGF is average in that the compares extended effect now
the was the also stable of over best-corrected KSI-XXX. with effect consistent generally duration of Similarly, intervals prolonged these vision
is bars best-corrected amount visual small clinical you to the as here, tends the by basis know the you might standard that we in on or a As see change can see and main a fluctuate within trials, you month-to-month error all expect.
particularly difficult often values presentations Slide and the not X because in investigators does additionally, to among in turning or and data subretinal or And of treatment height complete PED Phase AMD the high values prior mean the features retinal but reasons. in comparison flattening some average clear height it PED, of patients change eliminating the or intraretinal to when mean as of In with and or treatment can rather include be success is PED whether PEDs. the now and is exclude starting. these of the data thickness patients imply publications includes the OCT and OCT our not the study, XX. studies anatomic necessarily anti-VEGF disclosed reported CST very detachments not b across So PEDs the fluid, by epithelial pigment wet other
very high best-corrected change the microns So CST. this total OCT, presented than vision with more baseline, show the graph on PED i.e., and of and patients subjects CST AMD the the XXX wet that two a excluding slide,
[indiscernible] and full outliers overall mean center the in those CST corrected then, in lower a baseline narrower, baseline cohort, similar relative to that's subfield summary have two the OTT demonstrating weight slide. call, SCM OCT fitness, or of the over in not And response. cohort, and prior vision values sort are the value are but thickness curves so treatment are they time and So but shape patients at in the those patients the of these up then two are small
So overall, patients. wet the AMD with to really very the out week XX pleased we're data in
reporting the time. and Society, are thus essentially So the And follow-up that have AAO at are into we've successively on longest been ASR, these the the first now. group who and patients study recruited we've been looking Macula the patients
So there so we also the is wanted are the because the how show of far rest patients to in other cohort doing study.
So let's move to Slide XX.
So weeks through when patients have retinal anatomy. improvements studies, and considering the nice XX of larger the ongoing of group also who in data we've the seen first vision
So here's XX AMD of have patients wet who XX weeks reached follow-up.
XX we see baseline acuity can improvement micron from improvement X.X the visual have You and OCT. in letters
then of average very so subfield previously, through a an an the OCT you microns I to with improvement seven PEDs next two an weeks, high those thickness can see improvement on slide, if center XX exclude chart described of microns. XXX XX down letters And patients we and eye
we're OCT here, So we feel really vision and about in good treatment. the outcomes seeing KSI-XXX to response
potent retinal vision what effect on AMD overall, These patients. in a learned? have anti-VEGF data has both So demonstrate KSI-XXX that best-corrected collectively drying wet improvement we and
expect then with in baseline differences The appears with clinical with we the existing KSI-XXX, existing might you are when agents. durability substantially observing longer agents, especially and clinical of in considering effect benefit characteristics, line
the in measured randomized manner. So two are and the the key objectively and open-label, in vision is Phase OCT assessments dose we believe patients study study are to these the are because a because although representative levels reproducible standardized Xb results both
four, of is receiving A ongoing who pivotal an every each patients to after on six administered an proportion further doses. very compared the five monthly Phase four, even wet to supports of X every design retreatment high DAZZLE loading in KSI-XXX two also Xb, aflibercept AMD or extended wet treatment-naive our as which months regimen regimen, have month or without patients study, been three, five-month or AMD six to on
to move macular XX let's latest the now and edema. So diabetic Slide
XX either are nine initial the monthly of DRCR were loading per DME, required other ranibizumab, median therapy after doses first patients year every the remember labeled same of medicines year. monthly dosing approved patients, administered of [indiscernible] or of almost agents. National needed a you DME bevacizumab the collaborative about all DRCR.net and loading under monthly number as Eye to study month So six all a doses Aflibercept, for doses. might and in of they for currently And five treatment the tested Institute-funded in algorithm all injections
with DME KSI-XXX two-fold. in objective thus Our is
First, to doses, reduce beyond. second the extend the of in number and and to loading interval initiating treatment phase months or maintenance to the three then
So XX, DME. plot then for Slide and lane let's the swim turn to
November are the these So of data as X.
five not doses. observed treated been followed after after that patients We without have loading retreatment XX% long to KSI-XXX the yet receiving three doses DME initiating longer four months with of months the any most as retreatment or seven eyes have extended receiving to of including patients for as
So for what KSI-XXX date. field I'm was Lucentis we're on now, going excited about some to diabetic regional here DR and the DME the X U.S. Phase intravitreal studies potential back the for to in in based any eye medicine approved patients, there the personally worked seeing having for time disease really very before
visual OCT So the be to in XX, follow-up to and durable then the turning as acuity Slide continue well. data improvements
XX the DME to is in that So cut-off prior these one who are after the week week data for the XX, between data XX the week XX, the three to XX is this and week change period effect microns. average XX.X week CST observed between and XX in treatment was and week with only change And the phase, XX a XX. months patients reached between visit XX.X micron loading only small maintained,
a KSI-XXX. anti-VEGF effect KSI-XXX, was these that with over existing with extended prolonged stable compares loading doses consistent of duration given. the I this agents, consistent the also very favorably durability to of think of and best-corrected vision number again So intervals, Similarly, reduced is of effect particularly were it with
improvement Slide XX, improvement to of turning with OCT of patients of group study. the And encouraging consistent and who in an X.X of so best-corrected now the have and are vision somewhat through So bigger letters, XXX microns. those data XX ongoing of weeks first
So appears in expected durability observing clinical KSI-XXX DME the were these demonstrate with loading than in patients and the existing longer anti-VEGF collectively potent the the achieved KSI-XXX substantially with data effect a line we are benefit fewer with from doses. has results these again And medicines. agents existing
to given data these interval three every regimen pivotal five KSI-XXX approved will be loading on doses, care standard after an where doses. three every other design six-month aflibercept after compared on month loading of support a to its So study
Slide XX. to then retinal turn let's occlusion, on vein So
RVO AMD So on wet is and than disease levels of VEGF a which DME. has average intraocular higher
treatment And expect are labeled Xb then U.K. you that moreover, here recent the And as since and dosing well. highest so study remember for monthly frequency our a Phase we in and of would aflibercept patients associated study, of ranibizumab be with than trial called both effect demonstrated less monthly with bevacizumab maximal [indiscernible] loss treatment could OCT. or vision in that on central RVO dosing
with in is objective our KSI-XXX also two-fold. RVO So
First reduce extend number two doses, monthly. to current the the to treatment to or which compared and interval second the floating to of standard, beyond up months is
milligrams to thus as for the Phase the with Slide to after XX, longer lane to really swim three longer, data patients looking Xb X study, In I far all these have that or been encouraged our last months be RVO with so KSI-XXX of XX% extended observed months treated extended RVO. continue plot two So we've or by loading to well. eyes dose
center one that data. cut-off. XX XX prior patients the see week who OCT durable recent be On to Visual change three XX. in with microns, XX.X week observation slide, and the this and only most move Let's to acuity on the visit this In a is the reached to improvements dose. between last XX, In week treatment consistent RVO week thickness XX micron is the change follow-up loading week the period required subfield continue to months Slide XX OCT. is received data average effect XX in the with X.X we only between some loading that XX at after phase, treatment weeks and patients the maintained, the and
over duration prolonged over with of eye to consistent in consistent intervals and chart week favorably compares extended at eye are data which effect durability also was these lines from baseline again, best-corrected of of think existing KSI-XXX, letters, is the was again improvement the chart stable XX. average XX.X I observed So four medicines. with Similarly, these it effect
average to XXX we XX XX.X and of too. we data with XX, see letters in through have an XX, bigger pleased with OCT really have data Slide group improvement can then vision chart the these here patients thickness, eye and improvement patients a of we Looking week micron
line in RVO in the existing retinal These anti-VEGF KSI-XXX on that both medicines substantially overall again appears achieved expected in with than loading potent effect RVO effects and Clinical the So demonstrate patients. doses. collectively has existing durability vision a fewer were drying we have with longer with data And with improvement what the benefit learned? medicines.
be pivotal longer design or to standard every KSI-XXX a [indiscernible] support will where would compared interval potentially study data of these care So given monthly. months two on given
Okay.
that's and latest on So the efficacy across updates durability indications. the
at Slide XX, safety. look let's to Turning
study as X, patients with reported exposure. age be intraocular eye So in given no XX expected injections latest be intravitreal the dose inflammation Slide XXX anti-VEGF b patients Xa the multiple and XXX for across in serious ocular very Phase continues profile or diseases encouraging then or events is on safety these either consistent to and of KSI-XXX and to now November in single ranges. continues The to adverse update. Phase agents, for profile The with systemic that these with X program safety
here a maybe interesting Maybe the community antibodies or word about become more that's a immunogenicity since that's lately. of brief anti-drug in topic,
XX-Q. We have some more details in the
from early shown titers XXX three or very samples, at low have samples We've it's all minimum far XXX four four and representing positive. Only Phase the data. Xb samples from assay program, antibodies. the pre-existing have below so patients No required patients dilution. tested have anti-drug tested And Those subjects. Xa
retreatment very a loss safety data or ADAs or number positivity did of it's not with show OCT a So to for review finding. with clinical small three correlated these patients with to earlier ocular be non-ocular any of the either subjects correlated ADA vision, and need for of or efficacy, safety clinical the corresponding and date
into So the provide KSI-XXX. additional although an preliminary, those are safety data of window they
updates our presentation a website of also Phase IR of So XX-Q. available today course, I've part and that's Xb the that's on the of really study. of part presented the lot materials on is, All slide
evolution that the pivotal the phase with confidence So just XXXX of our then profile the the pleased and toward really in program move KSI-XXX I'm the end outcomes efficacy It the position. of meeting durability FDA you emerging forward results exciting today. continued and very discussions the development to gives those also I'm data. we're the we very summary, and with and are safety study designs with seeing longer-term with from accelerate have really from and sharing clinical us data pleased the
back I'll that, over it with to turn Victor. And
